文献速递中医内科中药与中成药合理使用

松参养心胶囊联合胺碘酮治疗心力衰竭合并室性心律失常的Meta分析

Clinical Efficacy and Safety of Shensong Yangxin Capsule-Amiodarone Combination on Heart Failure Complicated by Ventricular Arrhythmia: A Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · Front Pharmacol · 2021-02-22

本研究通过Meta分析评估松参养心胶囊联合胺碘酮治疗心力衰竭合并室性心律失常的疗效与安全性,纳入18项随机对照试验共1697例患者。结果显示联合组在提高总有效率、降低不良反应、室性早搏次数及QT离散度方面优于单用胺碘酮组,但在改善左室射血分数和降低NT-proBNP方面无显著差异。由于纳入研究方法学质量较差,证据尚不足以支持常规使用。

要点

  • 联合组总有效率优于胺碘酮组(RR=1.21,95%CI 1.16-1.27)。
  • 联合组不良反应更少(RR=0.65,95%CI 0.45-0.95)。
  • 左室射血分数和NT-proBNP两组无显著差异。

核心结论

  • 松参养心胶囊联合胺碘酮在提高总有效率和降低不良反应方面可能优于单用胺碘酮,但证据因方法学质量差而不充分。

研究设计与样本

  • 系统检索7个电子数据库(Cochrane Library、PubMed、EMBASE、中国生物医学文献数据库、中国知网、维普、万方)自建库至2020年6月1日,纳入18项随机对照试验共1697例心力衰竭合并室性心律失常患者。

主要发现

  • 联合组总有效率优于胺碘酮组(RR=1.21,95%CI 1.16-1.27,p<0.01)。
  • 联合组不良反应少于胺碘酮组(RR=0.65,95%CI 0.45-0.95,p=0.03)。
  • 联合组室性早搏次数(MD=170.96,95%CI 159.88-182.04,p<0.01)和QT离散度(MD=8.39,95%CI 6.91-9.87,p<0.01)改善优于胺碘酮组。
  • 两组左室射血分数(MD=4.32,95%CI -0.56-9.20,p=0.08)和NT-proBNP(SMD=0.17,95%CI -0.81-1.14,p=0.73)无显著差异。

关键数值与推荐

  • 主要结局为总有效率和不良反应,次要结局包括室性早搏次数、左室射血分数、NT-proBNP和QT离散度。
  • 采用Cochrane风险偏倚工具评估纳入研究质量,使用RevMan 5.3软件分析。
  • 联合组总有效率RR=1.21(95%CI 1.16-1.27,p<0.01),不良反应RR=0.65(95%CI 0.45-0.95,p=0.03)。
  • 联合组室性早搏MD=170.96(95%CI 159.88-182.04,p<0.01),QT离散度MD=8.39(95%CI 6.91-9.87,p<0.01)。
  • 左室射血分数MD=4.32(95%CI -0.56-9.20,p=0.08),NT-proBNP SMD=0.17(95%CI -0.81-1.14,p=0.73)。

临床怎么用

  • 对于心力衰竭合并室性心律失常患者,可考虑松参养心胶囊联合胺碘酮以可能提高疗效并减少不良反应,但需结合患者具体情况谨慎决策。
  • 鉴于证据质量有限,不应将联合治疗作为常规推荐,需等待更高质量研究验证。

局限性

  • 纳入的随机对照试验方法学质量较差,可能导致结果偏倚。
  • 证据整体不足,无法支持松参养心胶囊联合胺碘酮的常规使用。
  • 需要更多设计良好、样本合理、方法学质量高的临床研究验证总体效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Shensong Yangxin capsule (SSYX) is a well-known traditional Chinese patent medicine for treating arrhythmia. Recently, a flurry of randomized controlled trials (RCTs) of SSYX combined with amiodarone (SSYX-amiodarone) was reported in the treatment of heart failure (HF) complicated by ventricular arrhythmia (VA) in China. However, these RCTs have not been systematically evaluated. Therefore, this study aimed to evaluate the efficacy and safety of SSYX-amiodarone in the treatment of heart failure complicated by ventricular arrhythmia (HF-VA). Methods: Seven electronic literature databases (the Cochrane Library, PubMed, EMBASE, China Biomedical database web, China National Knowledge Infrastructure Databases, Chinese Scientific Journal database and Wanfang database) were searched from their inceptions to June 1, 2020 to identify RCTs of SSYX-amiodarone in the treatment of HF-VA. The primary outcomes included the total effective rate and adverse events (ADRs). The secondary outcomes included the frequency of ventricular premature complexes, left ventricular ejection fraction, N terminal pro Btype natriuretic peptide (NT-proBNP), and QT dispersion (QTd). The quality of the included RCTs was assessed using the Cochrane risk-of-bias tool. All data was analyzed using RevMan 5.3 software. The registration number of this protocol is PROSPERO CRD42020196689. Results: There are Eighteen trials involving 1,697 patients were included in this study. Meta-analysis showed that SSYX-amiodarone group was superior to the amiodarone group in improving the total effective rate [RR = 1.21; 95%CI (1.16, 1.27); p < 0.01], meanwhile reducing the ADRs [RR = 0.65; 95%CI (0.45, 0.95); p = 0.03], VPCs [MD = 170.96; 95%CI (159.88, 182.04); p < 0.01] and QTd [MD = 8.39; 95%CI (6.91, 9.87); p < 0.01]. No significant difference of enhancing LVEF [MD = 4.32; 95%CI (-0.56, 9.20); p = 0.08] and reducing NT-proBNP [SMD = 0.17; 95%CI (-0.81, 1.14); p = 0.73] was observed between SSYX-amiodarone and amiodarone group. Conclusions: Despite the apparent positive findings reported, the evidence provided by this meta-analysis was still insufficient to support the routine use of SSYX-amiodarone for HF-VA due to the poor methodological quality of included studies. The overall effect should to be verified in further through more well-design clinical studies with reasonable sample and good methodological quality.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Cao X, Zhou M, Liu H, et al. Clinical Efficacy and Safety of Shensong Yangxin Capsule-Amiodarone Combination on Heart Failure Complicated by Ventricular Arrhythmia: A Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2021. PMID: 33692689. doi:10.3389/fphar.2021.613922

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。